Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Global Blood Therapeutics stock (GBT)

Buy Global Blood Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Global Blood Therapeutics is a biotechnology business based in the US. Global Blood Therapeutics shares (GBT) are listed on the NASDAQ and all prices are listed in US Dollars. Global Blood Therapeutics employs 457 staff and has a trailing 12-month revenue of around $234.9 million.

Our top picks for where to buy Global Blood Therapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Global Blood Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – GBT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Global Blood Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Global Blood Therapeutics stock price (NASDAQ: GBT)

Use our graph to track the performance of GBT stocks over time.

Global Blood Therapeutics shares at a glance

Information last updated 2024-06-30.
Latest market close$68.49
52-week range$0.00 - $0.00
50-day moving average $63.70
200-day moving average $38.56
Wall St. target price$64.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.86

Is it a good time to buy Global Blood Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Global Blood Therapeutics price performance over time

Historical closes compared with the close of $68.49 from 2022-10-05

1 week (2024-07-11) N/A
1 month (2024-06-18) N/A
3 months (2024-04-18) N/A
6 months (2024-01-18) N/A
1 year (2023-07-18) N/A
2 years (2022-07-22) 103.48%
3 years (2021-07-22) 132.64%
5 years (2019-07-22) 22.28%

Global Blood Therapeutics financials

Revenue TTM $234.9 million
Gross profit TTM $191.4 million
Return on assets TTM -25.18%
Return on equity TTM -148.56%
Profit margin -137.3%
Book value $1.76
Market Capitalization $4.6 billion

TTM: trailing 12 months

Global Blood Therapeutics share dividends

We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months.

Global Blood Therapeutics share price volatility

Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 0.4634. This would suggest that Global Blood Therapeutics's shares are less volatile than average (for this exchange).

Global Blood Therapeutics overview

Global Blood Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.

Frequently asked questions

What percentage of Global Blood Therapeutics is owned by insiders or institutions?
Currently 2.464% of Global Blood Therapeutics shares are held by insiders and 111.412% by institutions.
How many people work for Global Blood Therapeutics?
Latest data suggests 457 work at Global Blood Therapeutics.
When does the fiscal year end for Global Blood Therapeutics?
Global Blood Therapeutics's fiscal year ends in December.
Where is Global Blood Therapeutics based?
Global Blood Therapeutics's address is: 181 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
What is Global Blood Therapeutics's ISIN number?
Global Blood Therapeutics's international securities identification number is: US37890U1088
What is Global Blood Therapeutics's CUSIP number?
Global Blood Therapeutics's Committee on Uniform Securities Identification Procedures number is: 37890U108

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site